Alexion, Boston, said Andexxa has the potential to become the "global standard of care" for patients who experience life-threatening bleeding while taking Factor Xa inhibitors like apixaban and rivaroxaban."By leveraging Alexionâ€™s strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders," Hantson said.